Angiotech: Data show Vascular Wrap cuts neointimal hyperplasia by 87.6%

By E. Janene Geiss

Philadelphia, Sept. 18 - Angiotech Pharmaceuticals, Inc. said Sunday that preclinical data related to its Vascular Wrap paclitaxel-eluting mesh and Lifespan graft technology platform showed an 87.6% reduction in neointimal hyperplasia in animals who received a paclitaxel-eluting mesh compared with animals who received no mesh.

Although synthetic grafts are used in about 40% of hemodialysis patients who require a permanent vascular access, primary patency rates remain poor, the Vancouver, B.C., biopharmaceutical company said in a news release.

Most graft failures are caused by growth of scar tissue inside the graft (neointimal hyperplasia) at the location where the graft is connected to the vein (the graft-vein anastomosis), and there are no proven treatments that effectively prevent it.

The purpose of this preclinical study was to evaluate the effect of the Vascular Wrap bioabsorbable mesh containing paclitaxel on inhibiting neointimal hyperplasia in an animal model of dialysis access failure. The data were presented Sunday at The Western Vascular Society 2006 annual meeting in La Jolla, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.